文献速递前列腺癌

雄激素剥夺联合放疗联合或不联合多西他赛治疗局限性高危前列腺癌:随机NRG肿瘤学RTOG 0521试验的长期随访

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
PubMed 文献 · Eur Urol · 2023-05-12

RTOG 0521 III期试验前瞻性随机纳入563例可评估的高危局限性前列腺癌患者(>50%为Gleason 9-10),比较2年ADT+EBRT与ADT+EBRT+六周期多西他赛。中位随访10.4年,总生存HR 0.89(90%CI 0.70-1.14;单侧log-rank P=0.22),10年生存率ADT+EBRT组64% vs ADT+EBRT+多西他赛组69%,限制性平均生存时间12年差异0.45年未达统计学显著(单侧P=0.053)。无病生存、远处转移及PSA复发风险均无显著差异。作者认为多西他赛不应用于高危局限性前列腺癌。

要点

  • 中位随访10.4年,总生存HR 0.89(90%CI 0.70-1.14;单侧P=0.22),无显著差异。
  • 10年生存率ADT+EBRT组64% vs ADT+EBRT+多西他赛组69%,RMST 12年差异0.45年(单侧P=0.053)。
  • 无病生存(HR 0.92)、远处转移(HR 0.84)及PSA复发风险(HR 0.97)均无显著差异。

核心结论

  • 中位随访10.4年,实验组与对照组临床结局无显著差异;作者认为多西他赛不应用于高危局限性前列腺癌,并认为可能需使用新型预测生物标志物开展进一步研究。

研究设计与样本

  • III期随机对照试验NRG Oncology RTOG 0521,前瞻性随机分配高危局限性前列腺癌患者(>50%为Gleason 9-10)至2年ADT+EBRT或ADT+EBRT+六周期多西他赛,共入组612例,563例符合条件并纳入改良意向治疗分析。

主要发现

  • 中位随访10.4年(存活者),总生存HR 0.89(90%CI 0.70-1.14;单侧log-rank P=0.22),10年生存率ADT+EBRT组64% vs ADT+EBRT+多西他赛组69%。
  • 12年限制性平均生存时间差异为0.45年,未达统计学显著(单侧P=0.053)。
  • 无病生存HR 0.92(95%CI 0.73-1.14)、远处转移HR 0.84(95%CI 0.73-1.14)、PSA复发风险HR 0.97(95%CI 0.74-1.29),均无显著差异。
  • 化疗组2例发生5级毒性,对照组0例。

关键数值与推荐

  • 总生存HR 0.89(90%CI 0.70-1.14;单侧log-rank P=0.22)。
  • 10年生存率:ADT+EBRT组64% vs ADT+EBRT+多西他赛组69%。
  • 12年限制性平均生存时间差异0.45年(单侧P=0.053)。
  • 无病生存HR 0.92(95%CI 0.73-1.14);远处转移HR 0.84(95%CI 0.73-1.14);PSA复发风险HR 0.97(95%CI 0.74-1.29)。

临床怎么用

  • 作者结论认为多西他赛不应用于高危局限性前列腺癌。
  • 作者认为可能需使用新型预测生物标志物开展进一步研究。

局限性

  • 原文报告存在非比例风险证据,因此进行了事后限制性平均生存时间分析。
  • 作者结论认为可能需使用新型预测生物标志物开展进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer. OBJECTIVE: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of androgen deprivation therapy (ADT) + external beam radiation therapy (EBRT) + docetaxel with ADT + EBRT. DESIGN, SETTING, AND PARTICIPANTS: High-risk localized prostate cancer patients (>50% of patients had Gleason 9-10 disease) were prospectively randomized to 2 yr of ADT + EBRT or ADT + EBRT + six cycles of docetaxel. A total of 612 patients were accrued, and 563 were eligible and included in the modified intent-to-treat analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was overall survival (OS). Analyses with Cox proportional hazards were performed as prespecified in the protocol; however, there was evidence of nonproportional hazards. Thus, a post hoc analysis was performed using the restricted mean survival time (RMST). The secondary endpoints included biochemical failure, distant metastasis (DM) as detected by conventional imaging, and disease-free survival (DFS). RESULTS AND LIMITATIONS: After 10.4 yr of median follow-up among survivors, the hazard ratio (HR) for OS was 0.89 (90% confidence interval [CI] 0.70-1.14; one-sided log-rank p = 0.22). Survival at 10 yr was 64% for ADT + EBRT and 69% for ADT + EBRT + docetaxel. The RMST at 12 yr was 0.45 yr and not statistically significant (one-sided p = 0.053). No differences were detected in the incidence of DFS (HR = 0.92, 95% CI 0.73-1.14), DM (HR = 0.84, 95% CI 0.73-1.14), or prostate-specific antigen recurrence risk (HR = 0.97, 95% CI 0.74-1.29). Two patients had grade 5 toxicity in the chemotherapy arm and zero patients in the control arm. CONCLUSIONS: After a median follow-up of 10.4 yr among surviving patients, no significant differences are observed in clinical outcomes between the experimental and control arms. These data suggest that docetaxel should not be used for high-risk localized prostate cancer. Additional research may be warranted using novel predictive biomarkers. PATIENT SUMMARY: No significant differences in survival were noted after long-term follow-up for high-risk localized prostate cancer patients in a large prospective trial where patients were treated with androgen deprivation therapy + radiation to the prostate ± docetaxel.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sartor O, Karrison TG, Sandler HM, et al. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023. PMID: 37179241. doi:10.1016/j.eururo.2023.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。